Progyny (NASDAQ:PGNY) EVP Allison Swartz Sells 2,199 Shares of Stock

Progyny, Inc. (NASDAQ:PGNY) EVP Allison Swartz sold 2,199 shares of Progyny stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $17.27, for a total transaction of $37,976.73. Following the completion of the transaction, the executive vice president owned 97,378 shares of the company’s stock, valued at $1,681,718.06. The trade was a 2.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Allison Swartz also recently made the following trade(s):

• On Tuesday, March 3rd, Allison Swartz sold 4,657 shares of Progyny stock. The shares were sold at an average price of $17.40, for a total transaction of $81,031.80.
• On Thursday, December 4th, Allison Swartz sold 530 shares of Progyny stock. The shares were sold at an average price of $24.59, for a total transaction of $13,032.70.

Progyny Price Performance

Shares of Progyny stock traded down $0.01 during trading hours on Thursday, reaching $17.78. The company had a trading volume of 1,168,133 shares, compared to its average volume of 1,579,020. The firm has a market cap of $1.46 billion, a PE ratio of 27.35, a price-to-earnings-growth ratio of 1.19 and a beta of 1.01. Progyny, Inc. has a one year low of $16.75 and a one year high of $28.75. The business has a fifty day simple moving average of $23.40 and a 200 day simple moving average of $23.00.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.10. The business had revenue of $318.40 million for the quarter, compared to analysts’ expectations of $314.26 million. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The firm’s quarterly revenue was up 6.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.42 EPS. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. On average, research analysts forecast that Progyny, Inc. will post 0.6 EPS for the current year.

Wall Street Analyst Weigh In

PGNY has been the subject of a number of recent analyst reports. Wall Street Zen upgraded shares of Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Citigroup upgraded Progyny to an “outperform” rating in a research note on Tuesday, January 20th. Zacks Research cut Progyny from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. JPMorgan Chase & Co. set a $35.00 price objective on shares of Progyny in a research report on Wednesday, January 21st. Finally, KeyCorp cut their price target on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday. Eight equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Progyny presently has an average rating of “Moderate Buy” and a consensus target price of $28.80.

Hedge Funds Weigh In On Progyny

Several institutional investors and hedge funds have recently bought and sold shares of the stock. River Road Asset Management LLC boosted its stake in shares of Progyny by 13.9% during the 4th quarter. River Road Asset Management LLC now owns 687,824 shares of the company’s stock valued at $17,663,000 after purchasing an additional 83,912 shares in the last quarter. Invesco Ltd. lifted its holdings in Progyny by 17.2% in the fourth quarter. Invesco Ltd. now owns 466,769 shares of the company’s stock worth $11,987,000 after buying an additional 68,473 shares during the period. Caitlin John LLC boosted its position in Progyny by 72.3% during the 4th quarter. Caitlin John LLC now owns 12,796 shares of the company’s stock valued at $329,000 after acquiring an additional 5,371 shares in the last quarter. EP Wealth Advisors LLC purchased a new position in shares of Progyny during the 4th quarter worth approximately $275,000. Finally, XTX Topco Ltd bought a new position in shares of Progyny in the 4th quarter worth approximately $3,058,000. 94.93% of the stock is currently owned by institutional investors.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.